Acamprosate Completed Phase 3 Trials for Autism Spectrum Conditions/Disorders / Fragile X Syndrome (FXS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01300923Acamprosate in Youth With Fragile X Syndrome